Ravi Rao
Director/Board Member bij DBV TECHNOLOGIES
Vermogen: 9 828 $ op 31-03-2024
Profiel
Dr. Ravi M. Rao is Chief Medical Officer bij Swedish Orphan Biovitrum AB en lid van The Royal College of Physicians. Hij zit in de Raad van Bestuur van DBV Technologies SA. Dr. Rao was voorheen werkzaam als Chief Medical Officer bij Aeglea Biotherapeutics, Inc. en als Head-Global Medical Affairs bij GlaxoSmithKline Plc. Hij behaalde zijn doctoraatsdiploma aan de Universiteit van Cambridge en een doctoraatsdiploma aan het Imperial College London.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
DBV TECHNOLOGIES SA
0.01% | 15-02-2023 | 6 837 ( 0.01% ) | 9 828 $ | 31-03-2024 |
Actieve functies van Ravi Rao
| Bedrijven | Functie | Begin |
|---|---|---|
| DBV TECHNOLOGIES | Director/Board Member | 19-05-2021 |
| AUTOLUS THERAPEUTICS PLC | Director/Board Member | 01-04-2024 |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Sitryx Therapeutics Ltd.
 Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01-04-2022 |
Eerdere bekende functies van Ravi Rao
| Bedrijven | Functie | Einde |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Chief Tech/Sci/R&D Officer | 01-01-2022 |
| SPYRE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 10-08-2020 |
| GSK PLC | Chief Tech/Sci/R&D Officer | 01-10-2019 |
| OXFORD BIOMEDICA PLC | Corporate Officer/Principal | - |
Opleiding van Ravi Rao
| Imperial College London | Doctorate Degree |
| University of Cambridge | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 6 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| GSK PLC | Health Technology |
| OXFORD BIOMEDICA PLC | Health Technology |
| DBV TECHNOLOGIES | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| AUTOLUS THERAPEUTICS PLC | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Sitryx Therapeutics Ltd.
Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Health Technology |
